Neuphoria Therapeutics downgraded to Neutral from Buy at Lucid Capital

Lucid Capital analyst Elemer Piros downgraded Neuphoria Therapeutics (NEUP) to Neutral from Buy with a price target of $2.30, down from $81, after the Phase 3 AFFIRM-1 trial of BNC210 for the acute treatment of social anxiety disorder failed to meet its primary endpoint. The study also did not show statistically significant results across secondary endpoints, the analyst tells investors in a research note.